Physician profile
Thomas Geisler
NPI 1740608538
$6,753.69
in general payments reported to CMS, 2019-2025
35 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,111 · 2020: $1,294 · 2021: $1,449 · 2022: $111 · 2023: $618 · 2024: $1,417 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,676 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,675.67 |
| Education | $113.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,275.37 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $823.38 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $801.56 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $472.96 | 2021-2025 | Exalt Model D, Spyglass, X-Tack Endoscopic Helix Tacking System |
| Phathom Pharmaceuticals, INC. | $305.72 | 2023-2025 | Voquezna |
| Pfizer INC. | $243.90 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $216.77 | 2020-2024 | |
| Janssen Biotech, INC. | $161.42 | 2019-2025 | Tremfya |
| Daiichi Sankyo INC. | $148.79 | 2019-2021 | |
| Genzyme Corporation | $138.70 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $128.03 | 2019-2025 | Linzess |
| Allergan, INC. | $118.50 | 2019 | |
| Merck Sharp & Dohme LLC | $105.95 | 2020-2023 | Dificid |
| Celgene Corporation | $88.40 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $87.02 | 2019-2024 | Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $72.31 | 2020-2021 | |
| Alfasigma USA, INC. | $64.54 | 2020-2021 | |
| Madrigal Pharmaceuticals | $64.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $58.64 | 2019-2023 | Rebyota |
| Fresenius Kabi USA, LLC | $57.49 | 2023-2024 | Idacio |
| Amgen INC. | $35.32 | 2023-2025 | Amjevita, Uplizna |
| Shionogi INC | $33.22 | 2020 | |
| Novo Nordisk INC | $28.98 | 2020-2025 | Wegovy |
| Concordia Pharmaceuticals INC. | $25.27 | 2019 | |
| Eusa Pharma (US) LLC | $25.21 | 2020 | |
| Mylan Institutional INC. | $24.72 | 2023 | Hulio |
| Nestle Healthcare Nutrition INC. | $23.37 | 2021 | |
| Axonics, INC. | $20.01 | 2021 | |
| Evoke Pharma, INC. | $19.10 | 2020 | |
| Ardelyx, INC. | $18.25 | 2025 | Ibsrela |
| Conmed Corporation | $14.83 | 2025 | Airseal |
| Celltrion USA INC. | $14.15 | 2024 | Zymfentra |
| Romark Laboratories, Lc | $13.24 | 2019 | |
| Medtronic, INC. | $12.82 | 2023 | Interstim |
| Astrazeneca Pharmaceuticals LP | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Geisler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.